Celsior与微停搏液在择期主动脉瓣置换术中的心肌保护对比分析
该回顾性观察研究纳入631例择期主动脉瓣置换术患者,比较Celsior晶体停搏液(412例)与全血连续微停搏液(219例)的心肌保护效果。结果显示Celsior组调整后术后死亡风险更低(OR 0.33,95%CI 0.15–0.76),肌钙蛋白T随阻断时间增加的幅度更小,且未观察到过敏反应或意外毒性。
要点
- Celsior组调整后术后死亡风险显著低于微停搏液组(OR 0.33,95%CI 0.15–0.76)。
- 肌钙蛋白T释放可准确预测术后死亡(AUC=0.85),且Celsior组随时间增加幅度更低。
- 两组术后正性肌力药或主动脉内球囊反搏使用无统计学显著差异。
核心结论
- 孤立使用晶体Celsior停搏液可能是主动脉瓣置换术中最佳且安全的心肌保护策略。
研究设计与样本
- 回顾性观察研究,纳入所有择期主动脉瓣置换术中采用Celsior或微停搏液心肌保护的患者,共631例。
主要发现
- Celsior组412例(65.3%),微停搏液组219例(34.7%)。
- 肌钙蛋白T释放准确预测术后死亡,受试者工作特征曲线下面积为0.85。
- 肌钙蛋白T随阻断时间延长而升高,Celsior组调整后的时间相关增幅更低。
- 术后正性肌力药物或主动脉内球囊反搏使用两组无统计学显著差异。
- Celsior组调整后术后死亡更低(比值比0.33;95%置信区间0.15至0.76)。
关键数值与推荐
- 主要终点为心肌保护替代指标和30天死亡;次要终点为Celsior安全性分析。
- 未观察到归因于Celsior的过敏反应,也无凝血病、肾功能不全、肝功能不全或脑病的意外毒性。
临床怎么用
- 在择期主动脉瓣置换术中,可考虑将孤立晶体Celsior停搏液作为心肌保护选择之一。
- 肌钙蛋白T释放可用于辅助预测术后死亡风险。
局限性
- 回顾性观察设计可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have analyzed the efficacy of crystalloid cardioplegic solutions, but the use of Celsior (Genzyme Corp, Boston, MA) as a crystalloid cardioplegic solution has not been evaluated. METHODS: In this observational retrospective study, Celsior crystalloid solution was compared with an all-blood continuous myocardial protection (microplegia). The study included all patients who underwent elective aortic valve replacement operations in whom the myocardial protection was Celsior or microplegia. The primary end points were surrogates of myocardial protection and death at 30 days. The secondary end point was the safety analysis of the use of Celsior. RESULTS: The study included 631 patients, divided in two groups: 219 (34.7%) with microplegia and 412 (65.3%) with Celsior. Troponin T release accurately predicted postoperative death (area under the receiver operating characteristic curve = 0.85). Troponin T increased with the duration of clamp time, and the adjusted time-related increase was lower in the Celsior group. There were no statistically significant differences in the postoperative use of inotropic medication or intraaortic balloon pump. Adjusted postoperative death was lower in Celsior group (odds ratio, 0.33; 95% confidence interval, 0.15 to 0.76). There were no allergic reactions attributed to Celsior and no unexpected toxicity with the use of Celsior (coagulopathy, renal dysfunction, liver dysfunction, or encephalopathy). CONCLUSIONS: Isolated crystalloid Celsior may be an optimal and safe myocardial protection strategy in aortic valve replacement operations.
引用
- López-Menéndez J, Miguelena J, Morales C, et al. Celsior Versus Microplegia: Analysis of Myocardial Protection in Elective Aortic Valve Replacement. Ann Thorac Surg. 2016. PMID: 27884411. doi:10.1016/j.athoracsur.2016.09.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。